178 related articles for article (PubMed ID: 36551262)
1. Comprehensive Analysis of Transcriptomics and Genetic Alterations Identifies Potential Mechanisms Underlying Anthracycline Therapy Resistance in Breast Cancer.
Liu Z; Gao J; Gu R; Shi Y; Hu H; Liu J; Huang J; Zhong C; Zhou W; Yang Y; Gong C
Biomolecules; 2022 Dec; 12(12):. PubMed ID: 36551262
[TBL] [Abstract][Full Text] [Related]
2. Cross-platform meta-analysis of multiple gene expression profiles identifies novel expression signatures in acquired anthracycline-resistant breast cancer.
Lee YS; Ryu SW; Bae SJ; Park TH; Kwon K; Noh YH; Kim SY
Oncol Rep; 2015 Apr; 33(4):1985-93. PubMed ID: 25695524
[TBL] [Abstract][Full Text] [Related]
3. Reflections on the development of resistance during therapy for advanced breast cancer. Implications of high levels of activity of docetaxel in anthracycline-resistant breast cancer patients.
Ravdin PM
Eur J Cancer; 1997 Aug; 33 Suppl 7():S7-10. PubMed ID: 9486096
[TBL] [Abstract][Full Text] [Related]
4. Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin.
Berge EO; Huun J; Lillehaug JR; Lønning PE; Knappskog S
Biochim Biophys Acta; 2013 Mar; 1830(3):2790-7. PubMed ID: 23246812
[TBL] [Abstract][Full Text] [Related]
5. Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer.
Knappskog S; Chrisanthar R; Løkkevik E; Anker G; Østenstad B; Lundgren S; Risberg T; Mjaaland I; Leirvaag B; Miletic H; Lønning PE
Breast Cancer Res; 2012 Mar; 14(2):R47. PubMed ID: 22420423
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of histone H2A and H2B pathways is associated with anthracycline sensitivity in breast cancer.
Braunstein M; Liao L; Lyttle N; Lobo N; Taylor KJ; Krzyzanowski PM; Kalatskaya I; Yao CQ; Stein LD; Boutros PC; Twelves CJ; Marcellus R; Bartlett JM; Spears M
Breast Cancer Res; 2016 Feb; 18(1):16. PubMed ID: 26852132
[TBL] [Abstract][Full Text] [Related]
7. CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer.
Chrisanthar R; Knappskog S; Løkkevik E; Anker G; Østenstad B; Lundgren S; Berge EO; Risberg T; Mjaaland I; Maehle L; Engebretsen LF; Lillehaug JR; Lønning PE
PLoS One; 2008 Aug; 3(8):e3062. PubMed ID: 18725978
[TBL] [Abstract][Full Text] [Related]
8. Increased cellular accumulation and distribution of amrubicin contribute to its activity in anthracycline-resistant cancer cells.
Mamidipudi V; Shi T; Brady H; Surapaneni S; Chopra R; Aukerman SL; Heise C; Sung V
Cancer Chemother Pharmacol; 2012 Apr; 69(4):965-76. PubMed ID: 22120960
[TBL] [Abstract][Full Text] [Related]
9. Competing endogenous RNA networks of CYP4Z1 and pseudogene CYP4Z2P confer tamoxifen resistance in breast cancer.
Zheng L; Li X; Meng X; Chou J; Hu J; Zhang F; Zhang Z; Xing Y; Liu Y; Xi T
Mol Cell Endocrinol; 2016 May; 427():133-42. PubMed ID: 26980484
[TBL] [Abstract][Full Text] [Related]
10. DNA repair signature is associated with anthracycline response in triple negative breast cancer patients.
Rodriguez AA; Makris A; Wu MF; Rimawi M; Froehlich A; Dave B; Hilsenbeck SG; Chamness GC; Lewis MT; Dobrolecki LE; Jain D; Sahoo S; Osborne CK; Chang JC
Breast Cancer Res Treat; 2010 Aug; 123(1):189-96. PubMed ID: 20582464
[TBL] [Abstract][Full Text] [Related]
11. Secreted cellular prion protein binds doxorubicin and correlates with anthracycline resistance in breast cancer.
Wiegmans AP; Saunus JM; Ham S; Lobb R; Kutasovic JR; Dalley AJ; Miranda M; Atkinson C; Foliaki ST; Ferguson K; Niland C; Johnstone CN; Lewis V; Collins SJ; Lakhani SR; Al-Ejeh F; Möller A
JCI Insight; 2019 Feb; 5(6):. PubMed ID: 30830863
[TBL] [Abstract][Full Text] [Related]
12. Role of p53 Codon72 SNP in breast cancer risk and anthracycline resistance.
Arfaoui A; Douik H; Kablouti G; Chaaben AB; Handiri N; Zid Z; Ouni N; Zouiouch F; Ayari F; Mamoughli T; Bouassida J; Abazza H; Harzallaha L; Guemira F
Anticancer Res; 2015 Mar; 35(3):1763-9. PubMed ID: 25750340
[TBL] [Abstract][Full Text] [Related]
13. Anthracycline resistance in breast cancer: clinical applications of current knowledge.
Ravdin PM
Eur J Cancer; 1995; 31A Suppl 7():S11-4. PubMed ID: 8562184
[TBL] [Abstract][Full Text] [Related]
14. Alterations in estrogen signalling pathways upon acquisition of anthracycline resistance in breast tumor cells.
Chewchuk S; Guo B; Parissenti AM
PLoS One; 2017; 12(2):e0172244. PubMed ID: 28196134
[TBL] [Abstract][Full Text] [Related]
15. Oncogene associated cDNA microarray analysis shows PRAME gene expression is a marker for response to anthracycline containing chemotherapy in patients with diffuse large B-cell lymphoma.
Kawano R; Karube K; Kikuchi M; Takeshita M; Tamura K; Uike N; Eto T; Ohshima K; Suzumiya J
J Clin Exp Hematop; 2009 May; 49(1):1-7. PubMed ID: 19474511
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of ANLN contributed to poor prognosis of anthracycline-based chemotherapy in breast cancer patients.
Wang Z; Chen J; Zhong MZ; Huang J; Hu YP; Feng DY; Zhou ZJ; Luo X; Liu ZQ; Jiang WZ; Zhou WB
Cancer Chemother Pharmacol; 2017 Mar; 79(3):535-543. PubMed ID: 28243684
[TBL] [Abstract][Full Text] [Related]
17. The effect of eIF3a on anthracycline-based chemotherapy resistance by regulating DSB DNA repair.
Chen J; Liu JY; Dong ZZ; Zou T; Wang Z; Shen Y; Zhuo W; Li XP; Xiao D; Liu HT; Chen X; Zhou HH; Liu ZQ; Zhang JT; Yin JY
Biochem Pharmacol; 2021 Aug; 190():114616. PubMed ID: 34022189
[TBL] [Abstract][Full Text] [Related]
18. Current options in treatment of anthracycline-resistant breast cancer.
Kröger N; Achterrath W; Hegewisch-Becker S; Mross K; Zander AR
Cancer Treat Rev; 1999 Oct; 25(5):279-91. PubMed ID: 10544072
[TBL] [Abstract][Full Text] [Related]
19. Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers.
Lehmann-Che J; André F; Desmedt C; Mazouni C; Giacchetti S; Turpin E; Espié M; Plassa LF; Marty M; Bertheau P; Sotiriou C; Piccart M; Symmans WF; Pusztai L; de Thé H
Oncologist; 2010; 15(3):246-52. PubMed ID: 20228131
[TBL] [Abstract][Full Text] [Related]
20. A four gene signature predicts benefit from anthracyclines: evidence from the BR9601 and MA.5 clinical trials.
Spears M; Yousif F; Lyttle N; Boutros PC; Munro AF; Twelves C; Pritchard KI; Levine MN; Shepherd L; Bartlett JM
Oncotarget; 2015 Oct; 6(31):31693-701. PubMed ID: 26372731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
